BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Emmaus Life Sciences, Inc. EMMA
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$12.5M
▼ 25.2% vs FY2024
EPS · FY25
$-0.12
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-60.2%
Dividend coverage
221.3×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 12.5M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 60 cents on every revenue dollar this year.
Per share
USD -0.12
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 221.3 times — the rest stayed in the company.
Profitability
—
Return on equity, FY2025
ROE
Operating margin1.9%
Net margin-60.2%
Return on assets-33.3%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−11.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.2%
−11.7%
+62.0%
+21.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+43.3%
Change, 10 years—
The share count grew 43% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 21.4M
total assets, end of FY2025
Total assetsUSD 21.4M
EquityUSD -63.6M
CashUSD 2.1M
Gross debtUSD 27.1M
Net debtUSD 25.0M
Current ratio0.11×
Net debt stands at -39% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
Operating income $B
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
·
·
·
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.12
−0.10
−0.07
−0.21
−0.32
30.00
−1.30
−1.97
−2.52
−9.26
−6.64
−0.03
−0.14
−1.81
−4.74
−0.16
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
−0.03
−0.03
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
−408.4
·
·
·
·
·
·
·
Shares out B
0.07
0.06
0.06
0.05
0.05
0.05
0.05
0.04
0.00
0.00
0.00
0.10
0.09
0.00
0.00
0.06
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed